Fulgent Genetics Inc (FLGT) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Revenue: $73.5 million in Q1 2025, compared to $76.2 million in Q4 2024. GAAP Gross Margin: 38.6%. Non-GAAP Gross Margin: 41%. GAAP Operating Expenses: $48.1 million in Q1 2025. Non-GAAP Operating Expenses: $37.4 million. Adjusted EBITDA Loss: $2.9 million in Q1 2025. Non-GAAP Income: $1.2 million, or $0.04 per share. Stock Repurchase: 646,000 shares repurchased